Just accepted for publication- Fiorucci S., et al- Novel dual CystLTR1 antagonist/GPBAR1 agonist effectively reverses liver steatosis- Frontiers in Pharmacology 2022
Precision Biotherapeutics SrL a Spinoff of the University of Perugia reports new preclinical data on its lead compound CHIN117 on liver steatosis CysLTR1-GPBAR1 agonist
Post più commentati